login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Percutaneous coronary intervention in patients with severe aortic stenosis: Implications for TAVI


Tuesday, 28 Feb 2012 11:24
Sachin Goel and Samir Kapadia
Sachin Goel and Samir Kapadia


By Sachin Goel and Samir Kapadia


Outcomes of percutaneous coronary intervention in patients with severe aortic stenosis and coronary artery disease have remained understudied. This is because surgical aortic valve replacement and concomitant coronary artery bypass grafting have been the main treatment for severe aortic stenosis and coronary artery disease until recently.


Transcatheter aortic valve implantation (TAVI) has emerged as a feasible treatment option for patients with severe aortic stenosis who are at high risk with conventional surgical aortic valve replacement. Over 30,000 TAVIs have been performed worldwide, however, there is no consensus regarding the management of significant coronary artery disease in this setting. Occasionally, high-risk patients with severe aortic stenosis undergo percutaneous coronary intervention when there are contraindications to surgery or when their symptoms are felt to be attributable to a significant degree to coronary artery disease. We recently reported our experience with percutaneous coronary intervention in patients with severe aortic stenosis.


We studied the short-term outcomes of 254 patients with severe aortic stenosis who underwent percutaneous coronary intervention at the Cleveland Clinic over 11 years, and compared these with a propensity matched group of 508 patients derived from a pool of 20,069 patients without aortic stenosis who underwent percutaneous coronary intervention during the same time period. The mean age was 75 years in both groups, and patients with severe aortic stenosis had a mean STS score of 13 with 38% of patients with an STS score ≥10. The indications for percutaneous coronary intervention in patients with severe aortic stenosis were: acute coronary syndrome (unstable angina in 41%, NSTEMI in 19%, STEMI in 6%), stable angina in 24% and progressive NYHA class III/IV heart failure in 43% patients when the symptoms were felt to be more attributable to coronary artery disease or these patients were deemed high risk for surgical aortic valve replacement. We found no difference in 30 day mortality post percutaneous coronary intervention in patients with and without severe aortic stenosis (4.3% versus 4.7%). In a subgroup analysis, patients with low ejection fraction (≤30%) had a high 30 day post percutaneous coronary intervention mortality of 15.4% compared to 1.2% in patients with ejection fraction >30%.



Additionally, patients with severe aortic stenosis and high STS score (≥10) had a higher 30 day post percutaneous coronary intervention mortality of 10.4% compared to no mortality in those with STS score <10. The majority of 30 day deaths in patients with aortic stenosis who underwent percutaneous coronary intervention were related to progressive cardiac and multiorgan failure. Complication rates of percutaneous coronary intervention were similar in patients with and without aortic stenosis.


The main take-home message of this study is that percutaneous coronary intervention can be performed in patients with severe aortic stenosis and coronary artery disease without an increase in short-term mortality or procedural complications compared to propensity matched patients without aortic stenosis, particularly in those with preserved ejection fraction or absence of comorbidities. Severe aortic stenosis patients with low ejection fraction and comorbidities should be considered as high-risk candidates for percutaneous coronary intervention. Further research is needed to identify which patients require revascularisation prior to TAVI and the timing of revascularisation. Our study indicates that if percutaneous coronary intervention is undertaken in these high-risk aortic stenosis patients, they should not wait for a long time without undergoing a definitive procedure for their aortic stenosis i.e. TAVI.


Sachin Goel is clinical associate, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, USA.


Samir Kapadia is professor of Medicine and director, Sones Cardiac Catheterization Laboratories, Cleveland Clinic Foundation, USA.




Add New Comment

Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies
Friday, 31 Jul 2015
Abbott Vascular has announced it has entered into an agreement to purchase Tendyne Holdings (focused on developing minimally invasive mitral valve replacement therapies) and secured an option to ... Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies

Features


Bifurcation lesions: When a two-stent technique is needed
Tuesday, 18 Aug 2015
The advent of second-generation drug-eluting stents and the associated improved safety and efficacy has meant that the risks of using two stents for bifurcation lesions has significantly decreased. M... Bifurcation lesions: When a two-stent technique is needed

Getting to grips with social media
Tuesday, 04 Aug 2015
Pascal Meier believes that social media is the logical next step from the internet—just as the internet has revolutionised connectivity, social media is revolutionising communication. In this ... Getting to grips with social media

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions